Welcome to our dedicated page for QUEST DIAGNOSTICS SEC filings (Ticker: DGX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Quest Diagnostics Incorporated filings document a public diagnostic information services company with common stock listed on the New York Stock Exchange under DGX. The company’s 8-K reports disclose operating results, guidance updates, investor presentation materials, dividends, share repurchase authorizations, senior unsecured debt issuance and other material agreements tied to its capital structure.
Proxy filings describe annual meeting proposals, director elections, board committee assignments, governance practices, executive compensation and the company’s strategy for diagnostic testing insights, healthcare-provider relationships, data assets, automation and artificial intelligence. The filing record also documents shareholder voting matters and formal changes in board composition.
Quest Diagnostics Inc. director Gary M. Pfeiffer received an award of 1,142 restricted stock units of common stock on May 20, 2026 at no cash cost, as part of his director compensation. After this grant, his direct holdings total 31,005 shares, which include shares acquired through dividend reinvestment under the Amended and Restated Deferred Compensation Plan for Directors.
Quest Diagnostics reported the results of its 2026 Annual Meeting of Stockholders held on May 20, 2026. All nominated directors were elected for terms expiring at the 2027 annual meeting, each receiving substantially more votes "for" than "against".
Stockholders approved the advisory resolution on executive officer compensation and ratified the appointment of PricewaterhouseCoopers as the company’s independent registered public accounting firm for 2026. A stockholder proposal requesting an independent board chairman did not receive sufficient support and was not approved.
Quest Diagnostics Incorporated entered into a material definitive agreement by issuing $500,000,000 aggregate principal amount of 5.000% senior notes due 2036. These notes are senior unsecured obligations that rank equally with the company’s other existing and future senior unsecured debt.
The notes mature on June 30, 2036, with interest paid at 5.000% on June 30 and December 30 each year, starting December 30, 2026. The indenture limits certain liens, sale-leaseback transactions, and major corporate restructurings, and requires Quest to offer to repurchase the notes at 101% of principal plus accrued interest upon a defined change of control triggering event.
Quest Diagnostics Incorporated has priced a public offering of $500 million aggregate principal amount of 5.000% senior notes due 2036 under its shelf registration statement. The company expects to receive net proceeds at closing on May 6, 2026, subject to customary conditions.
Quest plans to use the net proceeds for general corporate purposes, which may include repaying existing indebtedness, including its $500 million aggregate principal amount of 3.45% Senior Notes maturing on June 1, 2026. The company also entered into an underwriting agreement with Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC and Mizuho Securities USA LLC in connection with the offering.
Vanguard Capital Management filed a Schedule 13G reporting beneficial ownership of 8,274,567 shares of Quest Diagnostics Inc Common Stock. The filing states this equals 7.53% of the class as of 03/31/2026, with 1,128,895 shares for which Vanguard has sole voting power and 8,274,567 shares for which it has sole dispositive power. The filing lists affiliated Vanguard entities and notes holdings include securities held for Vanguard funds and managed accounts.
Vanguard Portfolio Management reports beneficial ownership of 6,096,629 shares of Quest Diagnostics Inc. Common Stock (CUSIP 74834L100), representing 5.54% of the class as reported in a Schedule 13G. The filing states sole voting power of 15,229 shares and sole dispositive power over the full 6,096,629 shares. The disclosure is signed by Ashley Grim on 04/29/2026 and describes holdings managed across Vanguard affiliates and funds.
Quest Diagnostics Incorporated is offering $500,000,000 aggregate principal amount of 5.000% senior notes due June 30, 2036. The notes accrue interest from May 6, 2026, pay semiannually and were priced at 98.751% of principal. Net proceeds are estimated at $490,505,000 and are expected to be used for general corporate purposes, which may include repayment of the $500,000,000 3.45% Senior Notes maturing on June 1, 2026. The notes are senior unsecured, will rank equally with other senior unsecured obligations, and will be issued in book-entry form through DTC. The offering includes customary redemption features, a change-of-control repurchase at 101%, and covenants limiting liens and certain sale-and-leaseback transactions.
Quest Diagnostics Incorporated is offering senior unsecured notes under a preliminary prospectus supplement dated April 27, 2026. The prospectus supplement describes the notes’ general terms including semiannual interest, optional redemption (including a Par Call Date provision), and a Change of Control repurchase right at 101% of principal plus accrued interest. Net proceeds are expected to be used for general corporate purposes and may include repayment of the Company’s $500 million 3.45% Senior Notes due June 1, 2026. The notes will rank equally with Quest Diagnostics’ other senior unsecured obligations and be structurally subordinated to subsidiary indebtedness. The prospectus incorporates by reference the Company’s 2025 Form 10-K risk factors and other filings.
Quest Diagnostics Executive Vice President & CFO Sam Samad reported an acquisition of 108 shares of common stock on April 20, 2026, at $194.698 per share. After this award, he holds 33,376 shares directly.
Footnotes state the transaction represents an award of restricted share units and reflects shares acquired through a dividend reinvestment plan administered by his broker, which he chose to report early rather than on a later Form 5.
Quest Diagnostics senior executive Patrick Plewman, SVP for Diagnostic Services, reported a small acquisition of company common stock. On April 20, 2026, he acquired 49 shares at $194.699 per share through a dividend reinvestment plan administered by his broker.
Following this transaction, Plewman directly holds 15,247 Quest Diagnostics shares. The filing notes that these dividend reinvestment plan shares are eligible for deferred reporting on Form 5 under Rule 16a-6, but he chose to report the acquisition early on this Form 4.